menu
    • menu
    [{"orgOrder":0,"company":"IMU Biosciences","sponsor":"Molten Ventures","pharmaFlowCategory":"D","amount":"$14.6 million","upfrontCash":"Undisclosed","newsHeadline":"IMU Biosciences Secures \u00a311.5 Million in Series A Funding to Revolutionise Immune Powered Precision Medicine","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"IMU Biosciences","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"IMU Biosciences \/ Molten Ventures","highestDevelopmentStatusID":"3","companyTruncated":"IMU Biosciences \/ Molten Ventures"}]

    Find Clinical Drug Pipeline Developments & Deals by IMU Biosciences

    Menu

    IMU Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            IMU Biosciences

                            United Kingdom arrow
                            Discovery on Target
                            Not Confirmed

                            IMU Biosciences

                            United Kingdom arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery Platform

                            Sponsor : Molten Ventures

                            Deal Size : $14.6 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            IMU Biosciences Secures £11.5 Million in Series A Funding to Revolutionise Immune Powered Precision Medicine

                            Details : The net proceeds will be used to revolutionise immune powered precision medicine by leveraging IMU's discovery platform, CytAtlas™ being applied across health and disease to advance translational research and accelerate the drug development process.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 24, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery Platform

                            Sponsor : Molten Ventures

                            Deal Size : $14.6 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth